Combination of irinotecan (CPT-11) and nedaplatin (NDP) for recurrent patients with uterine cervical cancer
Combination of irinotecan (CPT-11) and nedaplatin (NDP) for recurrent patients with uterine cervical cancer
复制标题
DOI：
10.1007/s10147-012-0487-4
复制
发表时间：
2013-12-01
影响因子：
3.3
通讯作者：
Suzuki, Nao
中科院分区：
文献类型：
--
作者：
Ohara, Tatsuru;Kobayashi, Yoichi;Suzuki, Nao
回顾性分析伊立替康（CPT-11）联合奈达铂（NDP）治疗复发性宫颈癌的临床疗效，CPT-11 60 mg/m2静脉滴注，第1、8、15天，NDP 80 mg/m2静脉滴注，第1天，每4周1次。中位年龄为57岁（范围29-80岁），患者的体能状态（PS）分别为18例PS 0，10例PS 1和1例PS 2。临床分期：Ib 1期3例，Ib 2期2例，IIa期2例，IIb期10例，IIIb期8例，IVb期4例。鳞癌27例，腺癌2例。关于3级或以上血液学毒性，分别在79.3%、96.6%和13.8%的病例中观察到中性粒细胞减少症、白细胞减少症和发热性中性粒细胞减少症。对于非血液学毒性，分别仅在1例病例中观察到恶心、厌食、关节疼痛和意识模糊，因此，7例病例未完成化疗。在26例具有临床可评价病变的病例中，有7例完全缓解，3例部分缓解，7例疾病稳定，9例疾病进展，临床缓解率为38.5%。中位无进展生存期为7个月（范围，0-38个月）。CPT-11和NDP的组合似乎是积极的复发性宫颈癌患者。
The clinical activity of combination of irinotecan (CPT-11) and nedaplatin (NDP) for recurrent patients with uterine cervical cancer was evaluated retrospectively.Intravenous CPT-11 was given at 60 mg/m(2) (days 1, 8, 15), followed by NDP 80 mg/m(2) (day 1), every 4 weeks.According to the medical records, 29 cases have received this regimen since 2000. Median age was 57 years (range, 29-80), and performance status (PS) of the patients was 18 cases with PS 0, 10 cases with PS 1, and 1 case with PS 2, respectively. Clinical stage was as follows: 3 cases of stage Ib1, 2 cases of Ib2, 2 cases of IIa, 10 cases of IIb, 8 cases of IIIb, and 4 cases of IVb. There were 27 cases of squamous cell carcinoma and 2 cases of adenocarcinoma. Concerning hematological toxicity of grade 3 or more, neutropenia, leukopenia, and febrile neutropenia were observed in 79.3 %, 96.6 %, and 13.8 % of cases, respectively. For nonhematological toxicity, nausea, anorexia, joint pain, and confusion were observed in only 1 case, respectively, and as a result, in 7 cases chemotherapy was not completed. Among 26 cases with clinically evaluable lesions, there were 7 complete responses, 3 partial responses, 7 stable disease, and 9 progressive disease; the clinical response rate was 38.5 %. Median progression-free survival was 7 months (range, 0-38 months).The combination of CPT-11 and NDP seems to be active for patients with recurrent uterine cervical cancer.